These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10702556)

  • 1. Multiple mutations conferring ciprofloxacin resistance in Staphylococcus aureus demonstrate long-term stability in an antibiotic-free environment.
    Jones ME; Boenink NM; Verhoef J; Köhrer K; Schmitz FJ
    J Antimicrob Chemother; 2000 Mar; 45(3):353-6. PubMed ID: 10702556
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.
    Schmitz FJ; Jones ME; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Fluit A; Verhoef J; Hadding U; Heinz HP; Köhrer K
    Antimicrob Agents Chemother; 1998 May; 42(5):1249-52. PubMed ID: 9593159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA, grlB, gyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus.
    Schmitz FJ; Hofmann B; Hansen B; Scheuring S; Lückefahr M; Klootwijk M; Verhoef J; Fluit A; Heinz HP; Köhrer K; Jones ME
    J Antimicrob Chemother; 1998 Apr; 41(4):481-4. PubMed ID: 9598779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A study on the resistance of Staphylococcus aureus and the mechanisms of its resistance to fluoroquinolone].
    Lei Y; Gui X; Feng G
    Zhonghua Nei Ke Za Zhi; 2001 Mar; 40(3):176-9. PubMed ID: 11798575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel ciprofloxacin-resistant, nalidixic acid-susceptible mutant of Staphylococcus aureus.
    Piddock LJ; Jin YF; Webber MA; Everett MJ
    Antimicrob Agents Chemother; 2002 Jul; 46(7):2276-8. PubMed ID: 12069989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms and frequency of resistance to gatifloxacin in comparison to AM-1121 and ciprofloxacin in Staphylococcus aureus.
    Ince D; Hooper DC
    Antimicrob Agents Chemother; 2001 Oct; 45(10):2755-64. PubMed ID: 11557465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efflux pump-mediated quinolone resistance in Staphylococcus aureus strains wild type for gyrA, gyrB, grlA, and norA.
    Muñoz-Bellido JL; Alonzo Manzanares M; Martínez Andrés JA; Guttiérrez Zufiaurre MN; Ortiz G; Segovia Hernández M; García-Rodríguez JA
    Antimicrob Agents Chemother; 1999 Feb; 43(2):354-6. PubMed ID: 9925531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased antibacterial activity of DW286, a novel fluoronaphthyridone antibiotic, against Staphylococcus aureus strains with defined mutations in DNA gyrase and topoisomerase IV.
    Yun HJ; Min YH; Jo YW; Shim MJ; Choi EC
    Int J Antimicrob Agents; 2005 Apr; 25(4):334-7. PubMed ID: 15784314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of mutations in grlA and gyrA topoisomerase genes with resistance to ciprofloxacin in epidemic and sporadic isolates of methicillin-resistant Staphylococcus aureus.
    Deplano A; Zekhnini A; Allali N; Couturier M; Struelens MJ
    Antimicrob Agents Chemother; 1997 Sep; 41(9):2023-5. PubMed ID: 9303407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular epidemiology of quinolone resistance and comparative in vitro activities of new quinolones against European Staphylococcus aureus isolates.
    Schmitz FJ; Fluit AC; Brisse S; Verhoef J; Köhrer K; Milatovic D
    FEMS Immunol Med Microbiol; 1999 Dec; 26(3-4):281-7. PubMed ID: 10575140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular diversity of quinolone resistance in genetically related clinical isolates of Staphylococcus aureus and susceptibility to newer quinolones.
    Guirao GY; Martínez Toldos MC; Mora Peris B; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    J Antimicrob Chemother; 2001 Feb; 47(2):157-61. PubMed ID: 11157899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.
    Ruiz J; Sierra JM; De Anta MT; Vila J
    Int J Antimicrob Agents; 2001 Aug; 18(2):107-12. PubMed ID: 11516932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activities of six quinolones and mechanisms of resistance in Staphylococcus aureus and coagulase-negative staphylococci.
    Linde HJ; Schmidt M; Fuchs E; Reischl U; Niller HH; Lehn N
    Antimicrob Agents Chemother; 2001 May; 45(5):1553-7. PubMed ID: 11302827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of gatifloxacin in an in vitro pharmacokinetic-pharmacodynamic model against Staphylococcus aureus strains either susceptible to ciprofloxacin or exhibiting various levels and mechanisms of ciprofloxacin resistance.
    Ba BB; Arpin C; Vidaillac C; Chausse A; Saux MC; Quentin C
    Antimicrob Agents Chemother; 2006 Jun; 50(6):1931-6. PubMed ID: 16723548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. grlA and gyrA mutations and antimicrobial susceptibility in clinical isolates of ciprofloxacin- methicillin-resistant Staphylococcus aureus.
    Coskun-Ari FF; Bosgelmez-Tinaz G
    Eur J Med Res; 2008 Aug; 13(8):366-70. PubMed ID: 18952518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus.
    Takahata M; Yonezawa M; Kurose S; Futakuchi N; Matsubara N; Watanabe Y; Narita H
    J Antimicrob Chemother; 1996 Sep; 38(3):543-6. PubMed ID: 8889728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms and frequency of resistance to premafloxacin in Staphylococcus aureus: novel mutations suggest novel drug-target interactions.
    Ince D; Hooper DC
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3344-50. PubMed ID: 11083638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staphylococcus aureus mutants selected by BMS-284756.
    Discotto LF; Lawrence LE; Denbleyker KL; Barrett JF
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3273-5. PubMed ID: 11600399
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [In vitro activity of new quinolones against clinical strains of Staphylococcus aureus of the wild type and with mutations characterized by gyrA, gyrB and grlA].
    Yagüe Guirao G; Martínez-Toldos MC; Alonso Manzanares MA; Gutiérrez Zufiaurre MN; Martínez-Andrés JA; Muñoz Bellido JL; García-Rodríguez JA; Segovia Hernández M
    Rev Esp Quimioter; 2000 Sep; 13(3):271-5. PubMed ID: 11086276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased expression of fibronectin-binding proteins by fluoroquinolone-resistant Staphylococcus aureus exposed to subinhibitory levels of ciprofloxacin.
    Bisognano C; Vaudaux PE; Lew DP; Ng EY; Hooper DC
    Antimicrob Agents Chemother; 1997 May; 41(5):906-13. PubMed ID: 9145842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.